IPP Bureau
Teva confirms efficacy and safety of Ajovy for prevention of migraine
By IPP Bureau - April 15, 2024
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Novartis tender offer for MorphoSys commences
By IPP Bureau - April 15, 2024
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
.jpg "Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations")
Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations
By IPP Bureau - April 14, 2024
This facility manufactures APIs & formulations of oncology and non-oncology products.
Briefs: Sun Pharma and Kimia Biosciences
By IPP Bureau - April 14, 2024
Sun Pharma's Dadra facility receives OAI status from US FDA
Merck India appoints Dhananjay Singh as MD Merck Life Science in India
By IPP Bureau - April 13, 2024
USFDA completes inspection of Lupin's Dabhasa facility with no observations
By IPP Bureau - April 13, 2024
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
CRISPR-based innovations drive $21 billion in pharmaceutical licensing deals over five years, reveals GlobalData
By IPP Bureau - April 12, 2024
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Generics gain ground, yet HCPs still favor branded drugs, finds GlobalData
By IPP Bureau - April 12, 2024
A significant proportion of healthcare professionals still tend to favor branded drugs
Pfizer announces positive results from Phase 3 Study of Abrysvo
By IPP Bureau - April 12, 2024
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Cupid to supply Rs. 23.07 crore female condoms in Brazil
By IPP Bureau - April 12, 2024
Total value of the supplies of FC will be US$ 2.773 million
KRAZATI in Combination with Cetuximab demonstrates targeted treatment option for KRAS G12C- colorectal cancer
By IPP Bureau - April 11, 2024
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer
By IPP Bureau - April 11, 2024
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Ginkgo Bioworks and Novo Nordisk to collaborate across R&D value chain
By IPP Bureau - April 11, 2024
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
